{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:43:17Z","timestamp":1761176597200,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Societat Catalano-Balear d'Oncologia. Acad\u00e8mia de Ci\u00e8ncies M\u00e8diques i de la Salut de Catalunya i de Balears."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.radonc.2025.110990","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T19:55:26Z","timestamp":1750276526000},"page":"110990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Isolated nodal failure in stage III non-small-cell lung cancer after proton therapy with or without durvalumab"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0170-9365","authenticated-orcid":false,"given":"Yuanyuan","family":"Lin-Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyra","family":"van Keeken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"van Loon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0128-3121","authenticated-orcid":false,"given":"Stephanie","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Reymen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"van Baardwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolien","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Degens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-1554","authenticated-orcid":false,"given":"Esther","family":"Kneepkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4965-290X","authenticated-orcid":false,"given":"Mirko","family":"Unipan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-6567","authenticated-orcid":false,"given":"Dirk De","family":"Ruysscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110990_b0005","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0010","unstructured":"Kristina Gregory N, Lisa Hang M, Aisner DL, Akerley W, Bauman JR, Bruno DS, et al. NCCN Guidelines Version 3.2024 Non-Small Cell Lung Cancer Continue NCCN Guidelines Panel Disclosures. 2024."},{"key":"10.1016\/j.radonc.2025.110990_b0015","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110990_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2017.06.003","article-title":"European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer","volume":"124","author":"De Ruysscher","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(24)00010-9","article-title":"Systematic endoscopic staging of mediastinum to guide radiotherapy planning in patients with locally advanced non-small-cell lung cancer (SEISMIC): an international, multicentre, single-arm, clinical trial","volume":"12","author":"Steinfort","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.radonc.2025.110990_b0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2010.02.007","article-title":"Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): a comparative analysis of toxicities and clinical outcomes","volume":"95","author":"Fernandes","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/01.coc.0000256691.27796.24","article-title":"A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer","volume":"30","author":"Yuan","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-016-0698-3","article-title":"Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF)","volume":"11","author":"Li","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0045","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ijrobp.2004.12.019","article-title":"Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study","volume":"62","author":"De Ruysscher","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110990_b0050","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2006.04.034","article-title":"Final results of a phase I\/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy","volume":"66","author":"Belderbos","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110990_b0055","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.radonc.2016.10.001","article-title":"Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study","volume":"121","author":"Martinussen","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1236361","article-title":"IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center","volume":"13","author":"Le Roy","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijrobp.2009.04.075","article-title":"Selective nodal irradiation on basis of 18FDG-PET scans in limited-disease small-cell lung cancer: a prospective study","volume":"77","author":"van Loon","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110990_b0070","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ijrobp.2012.10.003","article-title":"Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage i to III small cell lung cancer","volume":"85","author":"Reymen","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110990_b0075","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2006.01.052","article-title":"Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or Stage III non-small-cell lung cancer","volume":"65","author":"Chang","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110990_b0080","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/cncr.25848","article-title":"Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer","volume":"117","author":"Sejpal","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110990_b0085","doi-asserted-by":"crossref","first-page":"568","DOI":"10.5306\/wjco.v5.i4.568","article-title":"Proton beam therapy for locally advanced lung cancer: a review","volume":"5","author":"Schild","year":"2014","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2032","article-title":"Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non\u2013small cell lung cancer: final results of a phase 2 study","volume":"3","author":"Chang","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0095","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1002\/cncr.26080","article-title":"Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer","volume":"117","author":"Chang","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110990_b0100","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2014.07.045","article-title":"Clinical implementation of intensity modulated proton therapy for thoracic malignancies","volume":"90","author":"Chang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110990_b0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","article-title":"Proton therapy \u2013 present and future","volume":"109","author":"Mohan","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.radonc.2025.110990_b0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijrobp.2009.04.028","volume":"77","author":"Zhang","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110990_b0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2013.05.007","article-title":"Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach","volume":"107","author":"Langendijk","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2019.08.005","article-title":"Practical robustness evaluation in radiotherapy \u2013 a photon and proton-proof alternative to PTV-based plan evaluation","volume":"141","author":"Korevaar","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2024.104890","article-title":"Proton therapy of lung cancer patients \u2013 Treatment strategies and clinical experience from a medical physicist\u2019s perspective","volume":"130","author":"Taasti","year":"2025","journal-title":"Phys Med"},{"key":"10.1016\/j.radonc.2025.110990_b0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2019.09.005","article-title":"Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer","volume":"152","author":"Defraene","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0135","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-4-5","article-title":"Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer","volume":"4","author":"Sulman","year":"2009","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0140","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/jrr\/rrab063","article-title":"Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer","volume":"62","author":"Abe","year":"2021","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2025.110990_b0145","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.radonc.2019.03.029","article-title":"Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer","volume":"136","author":"Elhammali","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0150","doi-asserted-by":"crossref","unstructured":"Yu NY, DeWees TA, Liu C, Daniels TB, Ashman JB, Beamer SE, et al. Early outcomes of patients with locally advanced non-small cell lung cancer treated with intensity-modulated proton therapy versus intensity-modulated radiation therapy: The Mayo Clinic experience. Adv Radiat Oncol, vol. 5, Elsevier Inc; 2020, p. 450\u20138. Doi: 10.1016\/j.adro.2019.08.001.","DOI":"10.1016\/j.adro.2019.08.001"},{"key":"10.1016\/j.radonc.2025.110990_b0155","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110990_b0160","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cllc.2024.02.006","article-title":"Durvalumab consolidation after chemoradiotherapy in elderly patients with unresectable stage III NSCLC: a real-world multicenter study","volume":"25","author":"Park","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2025.110990_b0165","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ijrobp.2023.10.005","article-title":"Patterns of failure, low-volume relapse, and subsequent ablative management in locally advanced non-small cell lung cancer treated with definitive chemoradiation and consolidation immune checkpoint inhibitors","volume":"118","author":"Friedes","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110990_b0170","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jrr\/rrac057","article-title":"Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer","volume":"64","author":"Kishi","year":"2023","journal-title":"J Radiat Res"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025044949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025044949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:23:39Z","timestamp":1761128619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025044949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":34,"alternative-id":["S0167814025044949"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110990","relation":{},"ISSN":["0167-8140"],"issn-type":[{"type":"print","value":"0167-8140"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolated nodal failure in stage III non-small-cell lung cancer after proton therapy with or without durvalumab","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110990"}}